Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Conditions
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Trial Timeline
Nov 21, 2022 → Jun 1, 2026
NCT ID
NCT05568095About Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab is a phase 3 stage product being developed by Gilead Sciences for Advanced Upper Gastrointestinal Tract Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT05568095. Target conditions include Advanced Upper Gastrointestinal Tract Adenocarcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05568095 | Phase 3 | Active |
Competing Products
20 competing products in Advanced Upper Gastrointestinal Tract Adenocarcinoma